Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · IEX Real-Time Price · USD

2.975

+0.135 (4.75%)

At close: Apr 18, 2024, 4:00 PM

3.070

+0.095 (3.19%)

After-hours: Apr 18, 2024, 5:52 PM EDT

Century Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Revenue	2.24	5.2	0	0
Revenue Growth (YoY)	-57.01%	-	-	-
Gross Profit	2.24	5.2	0	0
Selling, General & Admin	34.71	31.86	19.24	9.5
Research & Development	92.71	97.17	75.65	39.68
Other Operating Expenses	21.37	10	0	4.72
Operating Expenses	148.78	139.03	94.88	53.9
Operating Income	-146.55	-133.83	-94.88	-53.9
Interest Expense / Income	0.54	1.43	1.28	0.38
Other Expense / Income	-12.29	-4.42	-0.38	-0.7
Pretax Income	-134.79	-130.84	-95.78	-53.58
Income Tax	1.88	0.09	0.04	0
Net Income	-136.67	-130.93	-95.82	-53.58
Shares Outstanding (Basic)	59	58	32	7
Shares Outstanding (Diluted)	59	58	32	7
Shares Change	2.70%	78.30%	332.95%	-
EPS (Basic)	-2.30	-2.27	-2.96	-7.16
EPS (Diluted)	-2.30	-2.27	-2.96	-7.16
Free Cash Flow	-102.08	-16.55	-133.97	-51.09
Free Cash Flow Per Share	-1.72	-0.29	-4.14	-6.83
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-6556.87%	-2574.17%	-	-
Profit Margin	-6115.12%	-2518.41%	-	-
Free Cash Flow Margin	-4567.52%	-318.37%	-	-
EBITDA	-122.4	-119.34	-89.92	-51.44
EBITDA Margin	-5476.69%	-2295.44%	-	-
Depreciation & Amortization	11.85	10.07	4.58	1.75
EBIT	-134.25	-129.41	-94.51	-53.19
EBIT Margin	-6006.80%	-2489.15%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).